Akums Drugs and Pharmaceuticals Limited

As of June 30, 2026, Akums Drugs and Pharmaceuticals Limited carries a market capitalization of 95.51B, placing it among publicly traded companies globally. Its enterprise value stands at 95.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Akums Drugs and Pharmaceuticals Limited's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Akums Drugs and Pharmaceuticals Limited has 153.10M shares outstanding.

As of June 30, 2026, Akums Drugs and Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 32.75.

As of June 30, 2026, Akums Drugs and Pharmaceuticals Limited trades at an EV/EBITDA multiple of 17.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 95.51B versus a market cap of 95.51B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.51M in revenue per employee across its workforce of 17,937.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Akums Drugs and Pharmaceuticals Limited recorded 1.33B in income tax expense. That works out to an effective tax rate of 31.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.26B, leaving 2.92B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Akums Drugs and Pharmaceuticals Limited's stock has gained approximately 44.30% over the past 52 weeks. The 50-day moving average sits at 767.02, while the 200-day moving average is 595.91.

Over the twelve months ended June 30, 2026, Akums Drugs and Pharmaceuticals Limited generated 45.02B in revenue and converted that into 2.92B in net income, yielding earnings per share of 19.11. EBITDA reached 5.48B, while operating income came in at 4.09B.

Over the twelve months ended June 30, 2026, Akums Drugs and Pharmaceuticals Limited posted a gross margin of 42.75, reflecting its pricing power and cost economics. The operating margin of 9.09 and net profit margin of 6.48 provide insight into operational efficiency.